Lung disease treatment product development continues to lead, and product sales are progressing steadily

Hangzhou, March 28, 2024 /PRNewswire/ -- March 28, 2024, a leader in precise interventional diagnosis and treatment of lung diseases in ChinaKunbo Healthcare(02216.HK) announced its annual results for the year ended December 31, 2023. During the reporting period, the company achieved product sales revenue of US$12.41 million, an increase of 32% over the previous year. Among them, the total sales revenue of products in mainland China was US$8.62 million, up 48% year on year.

In 2023, the company will firmly focus on the “navigation-diagnosis-treatment” industrial layout, and vigorously promote innovative research and development and clinical trials of lung disease treatment products to consolidate the company's leading position in the field of respiratory intervention. During the year, seizing the market opportunities brought about by the policy, various products were localized and approved for listing by the National Drug Administration (NMPA), reducing production costs, enriching the company's product sequence, and boosting market penetration, with a view to driving steady growth in sales revenue.

Therapeutic product development and clinical progress are still at the forefront of the world

Kunbo Medical continues to lead the world in product development and clinical trials for interventional treatment of lung diseases. In 2023, the company made significant progress in product development for interventional treatment of chronic obstructive pulmonary disease (COPD, COPD) and lung cancer, mainly:

The field of lung cancer treatment—RF II has been submitted for registration

The Zhiheng RF II pulmonary radiofrequency ablation system completed confirmatory clinical trial follow-up in the first quarter of 2023 and submitted for registration with the National Drug Administration (NMPA) in the fourth quarter. This product is the world's first transbronchial interventional treatment product for lung cancer. Its confirmatory clinical study results fully confirm the safety and efficacy of Zhiheng RF II in clinically treating lung cancer. Combined with the characteristics of minimally invasive radiofrequency interventional treatment, reproducible ablation, and the ability to be used in combination with other treatments, the development and launch of Zhiheng RF II will effectively push the lung cancer treatment threshold forward and provide patients with more new treatment options.

The field of COPD treatment—TLD pre-marketing clinical trials are progressing smoothly

China's first independently innovated pulmonary targeted denervation (TLD) system to treat acute exacerbation of COPD has completed the first pre-marketing clinical trial in July 2023. The clinical trial is scheduled to include 189 patients. As of December 31, 2023, more than 40 patients have been enrolled in more than 20 research centers.

With strong R&D and innovation capabilities, the company focuses on the field of lung disease treatment and consolidates its competitive advantage in R&D in the global respiratory intervention market. With the continuous launch of therapeutic products, it not only brings new lung disease solutions to patients, but also injects long-term impetus into the company's sustainable development and commercialization penetration.

The commercialization of listed products is progressing steadily

In 2023, the company fully launched the “Kunbo Plan” for respiratory intervention to achieve a comprehensive product layout of “positioning - arrival - diagnosis - treatment”, integrating the experience of products already on the market, and fully carrying out commercial implementation work. In the future, the company will continue to explore sales strategies for various products. With a comprehensive product portfolio, active marketing plans and efficient implementation capabilities, the company will achieve rapid admission of its products and a significant increase in sales revenue.

InterVapor

InterVapor The hot steam therapy system is the only implantless interventional treatment device for chronic obstructive pulmonary disease (COPD) in the world. 2023, InterVapor Commercial implantation has been carried out in over 20 hospitals in China, and about 100 hospitals have come into contact with using/testing the technology.

From InterVapor Since its launch, hospitals at all levels have gradually begun endobronchial endoscopic hot steam ablation (BTVA). BTVA surgery is easy to operate, takes a short time, and has good feedback after surgery. Some hospitals already have experience with multiple BTVA surgeries in a single day. In the future, with the gradual coverage of medical insurance in various regions and the popularization of patient efficacy, InterVapor The hot steam treatment system is expected to be widely used clinically in a large number of primary hospitals.

Navigation products

Kunbo Medical currently has 3 marketed products for real-time airway navigation: LungPoint, LungPoint Plus (known as Archimedes Lite outside of Asia), and LungPro (known as Archimedes outside of China). The commercialization of navigation products is progressing steadily through a combination of direct sales and distribution. During the reporting period, according to public statistics, the number of installed navigation systems of the company was still at the top of the Chinese market, with a market share of about 40%.

Consumables products

As of December 31, 2023, BroncTRU is a one-time use of a bronchoscopic dilatation catheter, “Fog Spring”“The disposable endoscopic atomization microcatheter and other consumables have been used in multiple scenarios in many hospitals in Shanghai, Shandong, Hunan and other places.

Localization and popularization of techniques unleash new momentum in the company

In 2023, the results of the company's localization strategy were initially revealed. Domestic version of LungPoint, domestic version of InterVaporNMPA registration certificate has been obtained one after another, and the domestic version of LungPro has submitted an application for NMPA registration. The implementation of equipment localization has fully unleashed the advantages of the company's production base in China, not only provided sufficient impetus for the company's gross margin, but also enriched the product sequence to meet the needs of the broader medical equipment market.

Continued domestic and international exchange activities vigorously promote the popularization of innovative techniques and enhance the company's brand influence. In 2023, Kunbo Medical carried out a series of academic exchange activities such as doctor training activities and summit forums at home and abroad to vigorously promote the company's product technical advantages and leading position in the industry. Under the joint promotion of a richer product lineup and gradual recognition of patient efficacy, Kunbo Medical greatly increased the awareness and penetration rate of the company's products in hospitals.

Looking forward to the future, the company will continue to aggressively promote brand promotion and commercialization of innovative products, promote the company's cost control and product sales through multiple means, enhance the company's overall competitive advantage, and release more business resilience.